Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882180 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
A Phase 1 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00882180 is a Phase 1 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT00882180, a Phase 1 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
Interventions
- DRUG ALN-VSP02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882180
The ClinicalTrials.gov registry entry for NCT00882180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALN-VSP02 is the first listed.
NCT00882180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882180 about?
NCT00882180 is a clinical study titled "Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement". The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
What is the current status of trial NCT00882180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2009-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00882180?
The interventions under investigation include: ALN-VSP02 (DRUG).
Who is sponsoring clinical trial NCT00882180?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.